what can we do more for the cost effectiveness of management of aki n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
What can we do more for the cost-effectiveness of management of AKI? PowerPoint Presentation
Download Presentation
What can we do more for the cost-effectiveness of management of AKI?

Loading in 2 Seconds...

play fullscreen
1 / 9

What can we do more for the cost-effectiveness of management of AKI? - PowerPoint PPT Presentation


  • 86 Views
  • Uploaded on

What can we do more for the cost-effectiveness of management of AKI?. 鄭昌錡 20120321. Phases of clinical biomarker evaluation and AKI studies. Siew ED, et al. JASN 2011. Comparative effectiveness research (CER) 比較效果研究. Definition.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

What can we do more for the cost-effectiveness of management of AKI?


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide4

Definition

The generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, or to improve the delivery of care.

slide6

Decision Tree

Outcome1

Outcome2

Clone 1

StandardTreatment

Probability 1

Outcome2

C1

Outcome1

Outcome1

p1

Probability 2

p2

Clone 2

Outcome2

Outcome2

C2

Outcome2

C1

Outcome1

p1

Clone 1

AVERAGE OUTCOMES

Life years (LY), QALY,…

Average costs

Probability 1

p2

Alternative

Outcome2

C2

Clone 2

Outcome1

Probability 2

slide7

BioSignature

Clone 1

StandardTreatment

Probability 1

C1

Outcme1

p1

Probability 2

p2

Clone 2

BIOMARKERS

Outcome2

C2

Outcme1

p1

Clone 1

Probability 1

p2

Alternative

Outcome2

C2

Clone 2

Outcme1

Probability 2

novel biomarkers in aki
Novel biomarkers in AKI

Parikh CR et al. CCM 2008

Chen YC, Fang JT, Yang CW. Taiwan Crit Care Med 2009

apply into cardiorenal syndrome

Recovery

Apply into Cardiorenal syndrome

CKD

Intervention

ESRD on RRT

AKI

Mortality

Recovery

AHF

AKI biomarkers

SMT

CKD

Survive

AMI

BNP

Pro-BNP

Cardiac echo

ESRD on RRT

Non-AKI

Mortality

Mortality

Survive

Recovery

Non-HF

CKD

Cardiac enzymes

CXR

ECG

CCU

Mortality

Intervention

ESRD on RRT

(n>1000)

AKI

Mortality

Recovery

AHF

AKI biomarkers

SMT

CKD

Survive

ESRD on RRT

BNP

Pro-BNP

Cardiac echo

Non-AKI

Mortality

Mortality

Non-AMI

Survive

Non-HF

Mortality

PS. AKI patients >300, Mortality patients >90